BCAX

8.4407.46%
MF

Michael F. Powell

Independent Chairman of the Board

Dr. Michael F. Powell, also known as Mike, was Director of Aeovian Pharmaceuticals, Inc. Dr. Powell is Independent Chairman of the Board of Bicara Therapeutics Inc. from August 2024, Director of Tensys Medical, Inc., Scientific Advisor of The Institute for OneWorld Health, Director of Alvine Pharmaceuticals, Inc., Director of Intellikine LLC, Chairman of Dauntless Pharmaceuticals, Inc., Director of Dauntless 2, Inc. and Board Member of Aerium Therapeutics. Dr. Powell was Venture Partner of Omega Fund Management, LLC until September 2025, having been Executive Partner of Omega Fund Management, LLC from August 2021 and was employed at Omega Fund Management, LLC from August 2021 to September 2025. He was Board Observer of Bicara Therapeutics Inc. until August 2024. Dr. Powell was Independent Chairman of Checkmate Pharmaceuticals, Inc. until May 31, 2022. He was General Partner and Managing General Partner of Sofinnova Investment, Inc. until August 2021 and was employed at Sofinnova Investment, Inc. from 1997 to August 2021. Dr. Powell was Independent Director of Ocera Therapeutics, Inc. from June 2006 to June 20, 2017. He was Member of Scientific Advisory Board of Aduro Biotech, Inc. until December 17, 2016. Dr. Powell was Director of Orexigen Therapeutics, Inc. from January 2004 to April 26, 2012. He was Director of Trius Therapeutics LLC from February 2007 to May 22, 2012. Dr. Powell was Director of Cibolan Gold Corporation from May 24, 2010 to December 17, 2010. He was Independent Director of Synlogic, Inc. from October 2012 to 2020. Dr. Powell was Independent Chairman of the Board of Galera Therapeutics, Inc. from July 2017 and Director of Galera Therapeutics, Inc. from November 28, 2016. He was Chairman of the Board of Mirna Therapeutics, Inc., having joined in October 2012. Dr. Powell was Director of Labrys Biologics, Inc. from January 03, 2013. He was Director of Corgentech Inc., having joined in December 2005. Dr. Powell was Director of Anesiva, Inc., having joined in December 2005. He was Director of Seagen Inc., having joined in April 1998. Dr. Powell was Director of Threshold Pharmaceuticals, Inc. from 2001 to November 2008. He was Director of Product Development of Epimmune Inc., Director of Catalyst Biosciences, Inc., Director of Saegis Pharmaceuticals, Inc., Director of DiObex, Inc., Director of Ascenta Therapeutics, Inc. and Director of XyloCor Therapeutics, Inc. He was Member of Scientific Advisory Board of Aradigm Corporation and Member of Advisory Board of Bill and Melinda Gates Foundation. Dr. Powell was Group Head of Drug Delivery of Genentech, Inc. and Senior Scientist of Syntex Corporation. Dr. Powell holds a Doctor of Philosophy in Physical Chemistry from University of Toronto in 1981 and a Bachelor of Science in Chemistry from Scarborough College in England.

Positions